EE03057B1 - Meetod standardiseeritud, eriti puhta ja teraapiliseks kasutamiseks sobiva inimese von Willebrandi teguri kontsentraadi tööstuslikuks valmistamiseks - Google Patents

Meetod standardiseeritud, eriti puhta ja teraapiliseks kasutamiseks sobiva inimese von Willebrandi teguri kontsentraadi tööstuslikuks valmistamiseks

Info

Publication number
EE03057B1
EE03057B1 EE9400004A EE9400004A EE03057B1 EE 03057 B1 EE03057 B1 EE 03057B1 EE 9400004 A EE9400004 A EE 9400004A EE 9400004 A EE9400004 A EE 9400004A EE 03057 B1 EE03057 B1 EE 03057B1
Authority
EE
Estonia
Prior art keywords
industrial production
therapeutic use
von willebrand
willebrand factor
particularly pure
Prior art date
Application number
EE9400004A
Other languages
English (en)
Estonian (et)
Inventor
Burnouf Thierry
Burnouf Miryana
Original Assignee
Centre Regional De Transfusion Sanguine De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion Sanguine De Lille filed Critical Centre Regional De Transfusion Sanguine De Lille
Publication of EE03057B1 publication Critical patent/EE03057B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EE9400004A 1991-03-08 1994-05-23 Meetod standardiseeritud, eriti puhta ja teraapiliseks kasutamiseks sobiva inimese von Willebrandi teguri kontsentraadi tööstuslikuks valmistamiseks EE03057B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (1)

Publication Number Publication Date
EE03057B1 true EE03057B1 (et) 1997-12-15

Family

ID=9410505

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400004A EE03057B1 (et) 1991-03-08 1994-05-23 Meetod standardiseeritud, eriti puhta ja teraapiliseks kasutamiseks sobiva inimese von Willebrandi teguri kontsentraadi tööstuslikuks valmistamiseks

Country Status (29)

Country Link
US (1) US5408039A (pl)
EP (1) EP0503991B1 (pl)
JP (1) JP3435668B2 (pl)
AT (1) AT407115B (pl)
AU (1) AU645172B2 (pl)
BE (1) BE1004178A3 (pl)
BR (1) BR9200770A (pl)
CA (1) CA2062340C (pl)
CZ (1) CZ283633B6 (pl)
DE (2) DE69227055T2 (pl)
DK (1) DK0503991T3 (pl)
EE (1) EE03057B1 (pl)
EG (1) EG20300A (pl)
ES (1) ES2121830T3 (pl)
FI (1) FI106721B (pl)
FR (1) FR2673632A1 (pl)
HU (1) HU215098B (pl)
IL (1) IL101043A (pl)
IT (1) IT1256692B (pl)
LT (1) LT3175B (pl)
NL (1) NL300394I1 (pl)
NO (1) NO301278B1 (pl)
NZ (1) NZ241701A (pl)
PL (1) PL168353B1 (pl)
RU (1) RU2088590C1 (pl)
SA (1) SA92120446B1 (pl)
SK (1) SK279533B6 (pl)
UA (1) UA27732C2 (pl)
ZA (1) ZA921430B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
RU2200028C2 (ru) * 2000-06-20 2003-03-10 Кировский НИИ гематологии и переливания крови Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
US9107902B2 (en) 2007-06-13 2015-08-18 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
KR101752508B1 (ko) * 2008-11-07 2017-06-29 백스터 인터내셔널 인코포레이티드 제8 인자 제형
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
CA2770609A1 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP6088435B2 (ja) 2010-12-15 2017-03-01 バクスアルタ ゲーエムベーハー 導電率グラディエントを用いる溶出液収集
DK2768521T3 (en) 2011-10-18 2016-10-24 Csl Behring Gmbh Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII
ES2600081T3 (es) 2011-10-18 2017-02-07 Csl Behring Gmbh Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
WO2015066769A1 (en) * 2013-11-08 2015-05-14 Csl Ltd. New method to concentrate von willebrand factor or complexes thereof
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP3362464B1 (en) * 2015-10-15 2021-04-28 Plasma Technologies LLC Methods for extracting proteins from blood plasma
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
RU2088590C1 (ru) 1997-08-27
NO920867L (no) 1992-09-09
ITTO920189A1 (it) 1993-09-06
CA2062340A1 (fr) 1992-09-09
HU9200767D0 (en) 1992-05-28
ATA43692A (de) 2000-05-15
CA2062340C (fr) 2000-05-09
HUT63176A (en) 1993-07-28
HU215098B (hu) 1998-09-28
CZ283633B6 (cs) 1998-05-13
LT3175B (en) 1995-02-27
NO301278B1 (no) 1997-10-06
BE1004178A3 (fr) 1992-10-06
EP0503991A1 (fr) 1992-09-16
ES2121830T3 (es) 1998-12-16
JPH0597696A (ja) 1993-04-20
FI106721B (fi) 2001-03-30
FR2673632A1 (fr) 1992-09-11
CS56892A3 (en) 1992-09-16
DK0503991T3 (da) 1999-06-14
DE69227055T2 (de) 1999-04-22
EG20300A (fr) 1998-10-31
PL168353B1 (pl) 1996-02-29
ITTO920189A0 (it) 1992-03-06
JP3435668B2 (ja) 2003-08-11
EP0503991B1 (fr) 1998-09-23
DE122009000034I2 (de) 2011-06-16
SK279533B6 (sk) 1998-12-02
UA27732C2 (uk) 2000-10-16
PL293738A1 (en) 1992-09-21
LTIP266A (en) 1994-07-15
US5408039A (en) 1995-04-18
IT1256692B (it) 1995-12-12
FI920992A0 (fi) 1992-03-06
IL101043A (en) 1997-02-18
ZA921430B (en) 1992-11-25
FR2673632B1 (pl) 1995-05-05
NZ241701A (en) 1994-10-26
NL300394I1 (nl) 2009-09-01
AU645172B2 (en) 1994-01-06
DE69227055D1 (de) 1998-10-29
AT407115B (de) 2000-12-27
BR9200770A (pt) 1992-11-17
SA92120446B1 (ar) 2004-05-04
NO920867D0 (no) 1992-03-05
DE122009000034I1 (de) 2010-04-08
AU1113192A (en) 1992-09-10
FI920992L (fi) 1992-09-09
IL101043A0 (en) 1992-11-15

Similar Documents

Publication Publication Date Title
EE03057B1 (et) Meetod standardiseeritud, eriti puhta ja teraapiliseks kasutamiseks sobiva inimese von Willebrandi teguri kontsentraadi tööstuslikuks valmistamiseks
FI951439L (fi) Mikro-organismit tryptofaanin tuottamista varten ja näiden valmistusmenetelmät
DE3669997D1 (de) Rollstuhl und anwendungsweise.
DE69422997D1 (de) Blutsauerstoffsystem und herstellverfahren
GB8624299D0 (en) Treatment of titanium dioxide
DK266787D0 (da) Respirator
FI941730L (fi) Uusia biologisia menetelmiä 7-ACA:n ja 7-ADAC:n valmistamiseksi
NO940996L (no) Fremgangsmåte for fremstilling, samt anvendelse av oksygenanriket gass
NO178499C (no) Fremgangsmåte for fremstilling og/eller rensing av clavulansyre og diaminosalter av clavulansyre
DK551986D0 (da) Patientkran
IT8349574A0 (it) Composti tripeptidici contententi acido piroglutaminico e triptofano, procedimentio di produzione ed applicazioni terapeutiche
FI914683A7 (fi) Substituoituja kromaaneja astman, niveltulehduksen ja sukulaistautien hoitoon
FI905768A0 (fi) Menetelmä titaanidioksidin valmistamiseksi
IT8519885A0 (it) Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
FI912322A7 (fi) Hyytymistekijä XIII:n puhdistus
EP0604505A4 (en) Production of selenium-72 and arsenic-72.
KR950701894A (ko) 하이드로 플루오로 알칸 제조 방법(production of hydrofluoroalkanes)
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DK387D0 (da) Respirator
DE69213637D1 (de) Herstellung von 2-Hydroxymandelsäuren und 2-Hydroxybenzaldehyden
DE69208096D1 (de) Herstellung von dialkyltellur und dialkylselen
AU1757592A (en) Therapeutic fragments of von willebrand factor
NO923455L (no) Indolsulfonamidsubstituert dihydropyridin, fremgangsmaate for fremstilling og anvendelse i legemidler

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20100523